Pharmaceutical company Pfizer of New York City announced last month that it is exploring alternatives for its Medical Technology Group that could include the divestiture of the business as a whole or in parts. The division includes Pfizer's Schneider
Pharmaceutical company Pfizer of New York City announced last month that it is exploring alternatives for its Medical Technology Group that could include the divestiture of the business as a whole or in parts. The division includes Pfizer's Schneider Worldwide business, which develops interventional radiology and cardiology products such as angioplasty balloon catheters. Other units in the business include Howmedica, which develops orthopedic devices, and American Medical Systems, a developer of urological implants. Pfizer was active in the medical imaging market in the 1980s, marketing such technologies as CT and mammography, but eventually exited the business.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.